Teva announces Phase III results

TEVA and partner H. Lundbeck A/S (CSE:LUN, Copenhagen, Denmark) announced positive results of a North American Phase III trial with TEVA's rasagiline selective MAO-B inhibitor to treat Parkinson's dis...